Newbury Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Newbury Pharmaceuticals has been growing earnings at an average annual rate of 2.9%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 227.4% per year.
Key information
2.9%
Earnings growth rate
2.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 30.5% |
| Revenue growth rate | 227.4% |
| Return on equity | -42.5% |
| Net Margin | -75.9% |
| Next Earnings Update | 10 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Newbury Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 29 Feb 24 | 23 | -17 | 24 | 0 |
| 30 Nov 23 | 21 | -17 | 23 | 0 |
| 31 Aug 23 | 10 | -19 | 21 | 0 |
| 31 May 23 | 12 | -19 | 20 | 0 |
| 28 Feb 23 | 7 | -18 | 18 | 0 |
| 30 Nov 22 | 6 | -17 | 16 | 0 |
| 31 Aug 22 | 6 | -15 | 15 | 0 |
| 31 May 22 | 3 | -13 | 13 | 0 |
| 28 Feb 22 | 3 | -12 | 11 | 0 |
| 30 Nov 21 | 3 | -10 | 9 | 0 |
| 31 Aug 21 | 3 | -6 | 6 | 0 |
Quality Earnings: NEWBRY is currently unprofitable.
Growing Profit Margin: NEWBRY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if NEWBRY's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare NEWBRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NEWBRY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: NEWBRY has a negative Return on Equity (-42.5%), as it is currently unprofitable.